HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNIFESP |
Texto Completo: | https://doi.org/10.1097/QAI.0000000000001499 https://repositorio.unifesp.br/handle/11600/58250 |
Resumo: | Background: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups. |
id |
UFSP_e9f85675c60157c8836f98d729ea53e4 |
---|---|
oai_identifier_str |
oai:repositorio.unifesp.br/:11600/58250 |
network_acronym_str |
UFSP |
network_name_str |
Repositório Institucional da UNIFESP |
repository_id_str |
3465 |
spelling |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA CollaborationHIVsuppressionpaediatricsadultsIeDEABackground: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups.UNSW, Kirby Inst, Sydney, NSW 2052, AustraliaJohns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USAFdn Huesped, Buenos Aires, DF, ArgentinaUniv Chile, Sch Med, Santiago, ChileFdn Arriaran, Santiago, ChileUniv Cape Town, Sch Publ Hlth & Family Med, Cape Town, South AfricaChildrens Hosp 2, Ho Chi Minh City, VietnamUniv Cape Town, Dept Paediat & Child Hlth, Cape Town, South AfricaUniv Calgary, Calgary, AB, CanadaYRGCARE Med Ctr, Madras, Tamil Nadu, IndiaUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, BrazilJohns Hopkins Univ, Dept Med, Div Infect Dis, Baltimore, MD USAUniv Stellenbosch, Dept Med, Div Infect Dis, Cape Town, South AfricaTygerberg Hosp, Cape Town, South AfricaUniv Bern, Inst Social & Prevent Med, Bern, SwitzerlandUniv Fed Sao Paulo, Pediat Infect Dis Div, Escola Paulista Med, Sao Paulo, BrazilWeb of ScienceU.S. National Institutes of Health's National Institute of Allergy and Infectious DiseasesEunice Kennedy Shriver National Institute of Child Health and Human DevelopmentNational Cancer InstituteCenters for Disease Control and Prevention, USAAgency for Healthcare Research and Quality, USAHealth Resources and Services Administration, USACanadian Institutes of Health Research, CanadaOntario Ministry of Health and Long Term CareGovernment of Alberta, CanadaIntramural Research Program of the National Cancer InstituteAustralian Government Department of Health and AgeingNCI: U01AI035004NCI: U01AI035039NCI: U01AI035040NCI: U01AI035041NCI: U01AI035042NCI: U01AI037613NCI: U01AI037984NCI: U01AI038855NCI: U01AI038858NCI: U01AI042590NCI: U01AI068634NCI: U01AI068636NCI: U01AI069432NCI: U01AI069434Centers for Disease Control and Prevention, USA: CDC-200-2006-18797Centers for Disease Control and Prevention, USA: CDC-200-2015-63931Agency for Healthcare Research and Quality, USA: 90047713Health Resources and Services Administration, USA: 90051652Canadian Institutes of Health Research, Canada: CBR-86906Canadian Institutes of Health Research, Canada: CBR-94036Canadian Institutes of Health Research, Canada: HCP-97105Canadian Institutes of Health Research, Canada: TGF-96118NCI: P30AI027757NCI: P30AI027763NCI: P30AI027767NCI: P30AI036219NCI: P30AI050410NCI: P30AI094189NCI: P30AI110527NCI: P30MH62246NCI: R01AA016893NCI: R01CA165937NCI: R01DA004334NCI: R01DA011602NCI: R01DA012568NCI: R24AI067039NCI: U01AA013566NCI: U01AA020790NCI: U01AI1031834NCI: U01AI034989NCI: U01AI034993NCI: U01AI034994NCI: M01RR000052NCI: U54MD007587NCI: UL1RR024131NCI: UL1TR000004NCI: UL1TR000083NCI: UL1TR000454NCI: UM1AI035043NCI: Z01CP010214NCI: Z01CP010176NCI: U01AI069907NCI: U01AI069923NCI: U01AI069924NCI: U01AI069918NCI: F31DA037788NCI: G12MD007583NCI: K01A1093197NCI: K23EY013707NCI: K24DA000432NCI: K24AI065298NCI: KL2TR000421NCI: N02CP055504NCI: U01AI103390NCI: U01AI103397NCI: U01AI103401NCI: U01AI103408NCI: U01DA036935NCI: U01HD032632NCI: U10EY008057NCI: U10EY008052NCI: U10EY008067NCI: U24AA020794Lippincott Williams & Wilkins2020-09-01T13:21:25Z2020-09-01T13:21:25Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion319-329https://doi.org/10.1097/QAI.0000000000001499Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017.10.1097/QAI.00000000000014991525-4135https://repositorio.unifesp.br/handle/11600/58250WOS:000416721800019engJaids-Journal Of Acquired Immune Deficiency SyndromesAustralasian HIV and AIDS ConferencePhiladelphiainfo:eu-repo/semantics/openAccessJiamsakul, AwachanaKariminia, AzarAlthoff, Keri N.Cesar, CarinaCortes, Claudia P.Davies, Mary-AnnViet Chau DoEley, BrianGill, JohnKumarasamy, NagalingeswaranMachado, Daisy Maria [UNIFESP]Moore, RichardProzesky, HansZaniewski, ElizabethLaw, Matthewreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2022-02-07T21:01:45Zoai:repositorio.unifesp.br/:11600/58250Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652022-02-07T21:01:45Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false |
dc.title.none.fl_str_mv |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
title |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
spellingShingle |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration Jiamsakul, Awachana HIV suppression paediatrics adults IeDEA |
title_short |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
title_full |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
title_fullStr |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
title_full_unstemmed |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
title_sort |
HIV Viral Load Suppression in Adults and Children Receiving Antiretroviral Therapy-Results From the IeDEA Collaboration |
author |
Jiamsakul, Awachana |
author_facet |
Jiamsakul, Awachana Kariminia, Azar Althoff, Keri N. Cesar, Carina Cortes, Claudia P. Davies, Mary-Ann Viet Chau Do Eley, Brian Gill, John Kumarasamy, Nagalingeswaran Machado, Daisy Maria [UNIFESP] Moore, Richard Prozesky, Hans Zaniewski, Elizabeth Law, Matthew |
author_role |
author |
author2 |
Kariminia, Azar Althoff, Keri N. Cesar, Carina Cortes, Claudia P. Davies, Mary-Ann Viet Chau Do Eley, Brian Gill, John Kumarasamy, Nagalingeswaran Machado, Daisy Maria [UNIFESP] Moore, Richard Prozesky, Hans Zaniewski, Elizabeth Law, Matthew |
author2_role |
author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Jiamsakul, Awachana Kariminia, Azar Althoff, Keri N. Cesar, Carina Cortes, Claudia P. Davies, Mary-Ann Viet Chau Do Eley, Brian Gill, John Kumarasamy, Nagalingeswaran Machado, Daisy Maria [UNIFESP] Moore, Richard Prozesky, Hans Zaniewski, Elizabeth Law, Matthew |
dc.subject.por.fl_str_mv |
HIV suppression paediatrics adults IeDEA |
topic |
HIV suppression paediatrics adults IeDEA |
description |
Background: Having 90% of patients on antiretroviral therapy (ART) and achieving an undetectable viral load (VL) is 1 of the 90: 90: 90 by 2020 targets. In this global analysis, we investigated the proportions of adult and paediatric patients with VL suppression in the first 3 years after ART initiation. Methods: Patients from the IeDEA cohorts who initiated ART between 2010 and 2014 were included. Proportions with VL suppression (<1000 copies/ mL) were estimated using (1) strict intention to treat (ITT)-loss to follow-up (LTFU) and dead patients counted as having detectable VL; and (2) modified ITT-LTFU and dead patients were excluded. Logistic regression was used to identify predictors of viral suppression at 1 year after ART initiation using modified ITT. Results: A total of 35,561 adults from 38 sites/16 countries and 2601 children from 18 sites/6 countries were included. When comparing strict with modified ITT methods, the proportion achieving VL suppression at 3 years from ART initiation changed from 45.1% to 90.2% in adults, and 60.6% to 80.4% in children. In adults, older age, higher CD4 count preART, and homosexual/bisexual HIV exposure were associated with VL suppression. In children, older age and higher CD4 percentage pre-ART showed significant associations with VL suppression. Conclusions: Large increases in the proportion of VL suppression in adults were observed when we excluded those who were LTFU or had died. The increases were less pronounced in children. Greater emphasis should be made to minimize LTFU and maximize patient retention in HIV-infected patients of all age groups. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2020-09-01T13:21:25Z 2020-09-01T13:21:25Z |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.1097/QAI.0000000000001499 Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017. 10.1097/QAI.0000000000001499 1525-4135 https://repositorio.unifesp.br/handle/11600/58250 WOS:000416721800019 |
url |
https://doi.org/10.1097/QAI.0000000000001499 https://repositorio.unifesp.br/handle/11600/58250 |
identifier_str_mv |
Jaids-Journal Of Acquired Immune Deficiency Syndromes. Philadelphia, v. 76, n. 3, p. 319-329, 2017. 10.1097/QAI.0000000000001499 1525-4135 WOS:000416721800019 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Jaids-Journal Of Acquired Immune Deficiency Syndromes Australasian HIV and AIDS Conference |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
319-329 |
dc.coverage.none.fl_str_mv |
Philadelphia |
dc.publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
publisher.none.fl_str_mv |
Lippincott Williams & Wilkins |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UNIFESP instname:Universidade Federal de São Paulo (UNIFESP) instacron:UNIFESP |
instname_str |
Universidade Federal de São Paulo (UNIFESP) |
instacron_str |
UNIFESP |
institution |
UNIFESP |
reponame_str |
Repositório Institucional da UNIFESP |
collection |
Repositório Institucional da UNIFESP |
repository.name.fl_str_mv |
Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP) |
repository.mail.fl_str_mv |
biblioteca.csp@unifesp.br |
_version_ |
1814268401053335552 |